Publication related to RSI or an RSI staff member

Derivation of whole blood biomonitoring equivalents for lithium for the interpretation of biomonitoring data.

INTRODUCTION: Lithium salts have numerous industrial uses and are also used in the treatment of bipolar disorders. The main source of lithium exposure to the general population is drinking water and foods. Lithium is nephrotoxic at higher doses. Thus, oral exposure guidelines for lithium have been derived, including ICH’s permitted daily exposure (PDE = 0.008 mg lithium/kg-bw/day) adopted by Health Canada and the United States Environmental Protection Agency’s (U.S. EPA) provisional peer reviewed toxicity value (PPRTV = 0.002 mg lithium/kg-bw/day), both based on human data. OBJECTIVE: To derive whole blood biomonitoring equivalents (BEs) associated with PDE and PPRTV to interpret population-level biomonitoring data in health risk context. METHOD: A simple kinetic relationship based on plasma clearance value (0.5 L/kg-bw/day) and the oral absorption fraction (100%) was used to derive blood BEs for PDE and PPRTV. RESULTS: This analysis resulted in BE values in plasma and whole blood of 16 and 10 mug/L, respectively, based on the PDE values developed by the Health Canada and of 4.2 and 2.7 mug/L, respectively, based on the PPRTV developed by U.S. EPA. CONCLUSION: The derived BE values can be used to interpret population-level biomonitoring data.

Authors

  • Ramoju, S, Ramoju S, Risk Sciences International, Ottawa, ON, Canada. Electronic address: sramoju@risksciences.com.

  • Andersen, M, Andersen M, Risk Sciences International, Ottawa, ON, Canada.

  • Poddalgoda, D, Poddalgoda D, Health Canada, Ottawa, ON, Canada.

  • Nong, A, Nong A, Health Canada, Ottawa, ON, Canada.

  • Karyakina, N, Karyakina N, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.

  • Shilnikova, N, Shilnikova N, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.

  • Krishnan, K, Krishnan K, Risk Sciences International, Ottawa, ON, Canada. Electronic address: kannan.krishnan@irsst.qc.ca.

  • Krewski, D, Krewski D, Risk Sciences International, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada.

YEAR OF PUBLICATION: 2020
SOURCE: Regul Toxicol Pharmacol. 2020 Mar;111:104581. doi: 10.1016/j.yrtph.2020.104581. Epub 2020 Jan 11.
JOURNAL TITLE ABBREVIATION: Regul Toxicol Pharmacol
JOURNAL TITLE: Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295 (Electronic) 0273-2300 (Linking)
VOLUME: 111
PAGES: 104581
PLACE OF PUBLICATION: Netherlands
ABSTRACT:
INTRODUCTION: Lithium salts have numerous industrial uses and are also used in the treatment of bipolar disorders. The main source of lithium exposure to the general population is drinking water and foods. Lithium is nephrotoxic at higher doses. Thus, oral exposure guidelines for lithium have been derived, including ICH's permitted daily exposure (PDE = 0.008 mg lithium/kg-bw/day) adopted by Health Canada and the United States Environmental Protection Agency's (U.S. EPA) provisional peer reviewed toxicity value (PPRTV = 0.002 mg lithium/kg-bw/day), both based on human data. OBJECTIVE: To derive whole blood biomonitoring equivalents (BEs) associated with PDE and PPRTV to interpret population-level biomonitoring data in health risk context. METHOD: A simple kinetic relationship based on plasma clearance value (0.5 L/kg-bw/day) and the oral absorption fraction (100%) was used to derive blood BEs for PDE and PPRTV. RESULTS: This analysis resulted in BE values in plasma and whole blood of 16 and 10 mug/L, respectively, based on the PDE values developed by the Health Canada and of 4.2 and 2.7 mug/L, respectively, based on the PPRTV developed by U.S. EPA. CONCLUSION: The derived BE values can be used to interpret population-level biomonitoring data.
COPYRIGHT INFORMATION: Crown Copyright (c) 2020. Published by Elsevier Inc. All rights reserved.
LANGUAGE: eng
DATE OF PUBLICATION: 2020 Mar
DATE OF ELECTRONIC PUBLICATION: 20200111
DATE COMPLETED: 20201001
DATE REVISED: 20201001
MESH DATE: 2020/10/02 06:00
EDAT: 2020/01/15 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: S0273-2300(20)30007-6 [pii] 10.1016/j.yrtph.2020.104581 [doi]
OWNER: NLM

Related RSI Experts

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski

Nataliya Karyakina

Senior Toxicologist, Health Risk Analyst

Dr. Nataliya Karyakina is a Senior Toxicologist and Health Risk Analyst at Risk Sciences International (RSI), where she has served since 2008. She plays a central role in RSI’s work at the intersection of chemical safety, regulatory science, and human...
Read More about Nataliya Karyakina

Natalia (Natasha) Shilnikova

Senior Health Risk Analyst

Dr. Natalia (Natasha) Shilnikova is a Senior Health Risk Analyst at Risk Sciences International (RSI), where she has contributed since 2011 to some of the organization’s most analytically demanding and policy-relevant projects. With a background in medicine and a PhD...
Read More about Natalia (Natasha) Shilnikova